Clinical Trial Detail

NCT ID NCT02300610
Title Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Cisplatin + Gemcitabine

Enzalutamide

Age Groups: adult

No variant requirements are available.